STEPHEN KRAMER
Psychiatric at San Felipe St, Houston, TX
License number
Texas E 0341
Category
Psychiatric
Type
Psychiatry
Address
Address
5847 San Felipe St STE 2000, Houston, TX 77057
Phone
(713) 952-3300
Personal information
See more information about STEPHEN KRAMER at radaris.comName
Address
Phone
4523 Spinks Creek Ln, Spring, TX 77388
4425 Effie St, Bellaire, TX 77401
9104 Breeze Point Cv, Austin, TX 78759
820 Redcedar Way Dr, Coppell, TX 75019
8012 Rocking Horse Ln, Fair Oaks, TX 78015
Organization information
See more information about STEPHEN KRAMER at bizstanding.comStephen Kramer
2623 Gln Hvn Blvd, Houston, TX 77025
Categories:
Insurance, Insurance Agents & Brokers, Insurance Consultants & Advisors
Phone:
(713) 662-3888 (Phone)
Stephen Kramer J
5847 San Felipe St, Houston, TX 77057
Industry:
Medical Doctor's Office
Owner:
Stephen J. Kramer Owner, inactive
Professional information
Dr. Stephen J Kramer, Houston TX - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
KRAMER CLINIC
5847 San Felipe St SUITE 3147, Houston 77057
(713) 952-3300 (Phone), (713) 977-1574 (Fax)
5847 San Felipe St SUITE 3147, Houston 77057
(713) 952-3300 (Phone), (713) 977-1574 (Fax)
Certifications:
Psychiatry, 1977
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Virginia Commonwealth University / Medical College of Virginia School of Medicine
Graduated: 1967
Maimonides Hosp Ctr
Montefiore Hosp
Virginia Commonwealth University / Medical College of Virginia School of Medicine
Graduated: 1967
Maimonides Hosp Ctr
Montefiore Hosp
Methods For Treating Psychological Disorders Using Bioactive Metabolites Of Gepirone
US Patent:
6534507, Mar 18, 2003
Filed:
Nov 13, 2000
Appl. No.:
09/709741
Inventors:
Stephen J. Kramer - Houston TX
Louis F. Fabre - Houston TX
Edward H. Ruediger - Greefield Park, CA
Joseph P. Yevich - Southington CT
Louis F. Fabre - Houston TX
Edward H. Ruediger - Greefield Park, CA
Joseph P. Yevich - Southington CT
Assignee:
Fabre-Kramer Pharmaceuticals, Inc. - Houston TX
International Classification:
A61K 31506
US Classification:
51425214, 51425218
Abstract:
Bioactive gepirone metabolites, such as 3-OH gepirone (4,4,-dimethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione), and their pharmaceutically acceptable salts and hydrates, can be used to alleviate psychological disorders or the symptoms thereof. The use of these compounds provides advantages over other therapeutic azapirones as they possess superior bioavailability, faster onset of action, and more stable plasma levels when administered to a mammal.
Use Of Bioactive Metabolites Of Gepirone For The Treatment Of Psychological Disorders
US Patent:
2003022, Nov 27, 2003
Filed:
Feb 7, 2003
Appl. No.:
10/149962
Inventors:
Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US
Edward Ruediger - Greenfield Park, CA
Joseph Yevich - Southington CT, US
Louis Fabre - Houston TX, US
Edward Ruediger - Greenfield Park, CA
Joseph Yevich - Southington CT, US
International Classification:
A61K031/496
US Classification:
514/252180
Abstract:
Bioactive gepirone metabolites, such as 3-OH gepirone (4,4,dethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione), and their pharmaceutically acceptable salts and hydrates, can be used to alleviate psychological disorders or the symptoms thereof. The use of these compounds provides advantages over other therapeutic azapirones as they possess superior bioavailability, faster onset of action, and more stable plasma levels when administered to a mammal.
Nasally Administrable Compositions Of Zolpidem And Methods Of Use
US Patent:
2008024, Oct 9, 2008
Filed:
Jun 16, 2008
Appl. No.:
12/139851
Inventors:
Stephen J. KRAMER - Houston TX, US
Louis F. Fabre - Houston TX, US
Louis F. Fabre - Houston TX, US
Assignee:
Fabre Kramer Pharmaceutical, Inc. - Houston TX
International Classification:
A61K 31/437, A61K 9/12
US Classification:
424 43, 514300
Abstract:
The present invention provides a method for inducing sleep, by nasally administrating to a subject in need thereof a pharmaceutical composition containing zolpidem, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.
Gepirone-Er Treatment Of Major Depression In Patients Taking Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
US Patent:
2013015, Jun 13, 2013
Filed:
Dec 10, 2012
Appl. No.:
13/709986
Inventors:
Stephen J. Kramer - Houston TX, US
Assignee:
Fabre-Kramer Pharmaceuticals.Inc. - Houston TX
International Classification:
A61K 31/506, A61K 45/06
US Classification:
51425218
Abstract:
A method of treatment of depression in a person also taking non-Steroidal anti-inflammatory drugs (NSAIDs) by administering gepirone as either a short term or long term therapy.
Nasally Administrable Compositions Of Zolpidem And Methods Of Use
US Patent:
2004024, Dec 2, 2004
Filed:
Mar 17, 2004
Appl. No.:
10/801856
Inventors:
Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US
Louis Fabre - Houston TX, US
Assignee:
Fabre Kramer Pharmaceutical, Inc. - Houston TX
International Classification:
A61L009/04, A61K031/4745
US Classification:
424/045000, 514/303000
Abstract:
One embodiment of the present invention provides a pharmaceutical composition for nasal administration, which includes zolpidem, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form. Another embodiment of the present invention provides a method for inducing sleep, which includes nasally administering to a subject in need thereof a pharmaceutical composition, which includes zolpidem, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.
5Ht1A Agonists For Treatment Of High Cholesterol
US Patent:
2013026, Oct 10, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/841161
Inventors:
Stephen J. KRAMER - Houston TX, US
Lou SMITH - Houston TX, US
Lou SMITH - Houston TX, US
Assignee:
FABRE-KRAMER PHARMACEUTICALS, INC. - Houston TX
International Classification:
A61K 31/506
US Classification:
51425218, 51425214
Abstract:
A method of treating and/or lowering elevated cholesterol by administering a therapeutically effective amount of at least one 5HTreceptor agonist to a subject in need thereof as either a short term or long term therapy. Also, a method of maintaining clinically acceptable cholesterol levels, or cholesterol levels below an elevated amount, by administering a therapeutically effective amount of at least one 5HTreceptor agonist to a subject in need thereof as either a short term or long term therapy.
Extended Release Compositions
US Patent:
2005009, May 5, 2005
Filed:
Jun 25, 2004
Appl. No.:
10/875384
Inventors:
Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US
Louis Fabre - Houston TX, US
Assignee:
Fabre Kramer Pharmaceuticals, Inc. - Houston TX
International Classification:
A61K031/506, A61K009/20
US Classification:
424464000, 514252190
Abstract:
A pharmaceutical composition is provided, which includes: at least one active ingredient selected from the group including adatanserin, a compound having formula I, a compound having formula II, abaperidone, pharmaceutically acceptable salt thereof, prodrug thereof, and a mixture thereof; at least one high or medium viscosity hydroxypropylmethylcellulose (HPMC); at least one high or medium viscosity hydroxyethylcellulose (HEC); wherein the HPMC and HEC are present in a HPMC/HEC weight ratio ranging from 1/0.5 to 1/1.5; wherein adatanserin, abaperidone, and the compounds having formulas (I) and (II) are defined herein.
High-Dosage Extended-Release Formulation Of Gepirone
US Patent:
2006009, May 11, 2006
Filed:
Nov 5, 2004
Appl. No.:
10/981663
Inventors:
Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US
Louis Fabre - Houston TX, US
Assignee:
Fabre-Kramer Pharmaceuticals, Inc. - Houston TX
International Classification:
A61K 31/506, A61K 9/14
US Classification:
424488000, 514252180
Abstract:
The present invention relates to high-dosage extended-release formulation of gepirone and methods of treating major depression by administering the same to a subject in need thereof. More specifically, the present invention relates to a high-dosage extended-release tablet form of gepirone. The present invention also relates to a method of treating depression in mammals by administering to a subject in need thereof an effective amount the high-dosage extended-release formulation of gepirone in accordance with the present invention.
Methods For Treating Attention Deficit Disorder
US Patent:
2004000, Jan 1, 2004
Filed:
Jun 28, 2002
Appl. No.:
10/183527
Inventors:
Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US
Louis Fabre - Houston TX, US
Assignee:
Fabre Kramer Pharmaceutical, Inc. - Houston TX
International Classification:
A61K031/506, A61K031/4747
US Classification:
514/252150, 514/278000
Abstract:
The present invention relates to a method for treatment of attention deficit disorder by administering certain 5-HTreceptor agonists